Our goal is to provide coating technology to effectively prevent hospital acquired infections from biofilm fouling of indwelling medical devices
Our CeraShield coated Biofilm-Resistant Endotracheal Tube, specifically designed to combat Ventilator-Associated Pneumonia (VAP), the most common, deadly HAI in ICU. VAP adds over Ten Billion Dollars in annual global treatment costs.
FDA Has Designated CeraShield Endotracheal Tube (ETT) As A “Breakthrough Device”. Cerashield ETT Is Cleared For Routine Clinical Use In Brazil, Canada, Colombia And UAE.
Overview
As an integral part of N8 Biosciences, a holding company committed to the extensive application of Ceragenins, N8 Biosciences is making strides in two key areas :
- The development of CeraShield, a specialized coating for medical devices, aimed at preventing infections.
- Through our subsidiary, Kinnear Pharmaceuticals (www.kinnearpharma.com), we're advancing therapeutic research and drug development. Our focus is on creating treatments for a range of conditions, including cystic fibrosis (CF) and Kostmann’s disease, leveraging the unique properties of Ceragenins that mimic the activity of naturally occurring innate immune system compounds such as LL-37.
Science
Ceragenins A Synthesis of Nature and Innovation
Inspired by nature
Unique capabilities
Proven and patented
Structure
Pipeline
The CeraShield ETT is designed to prevent Ventilator Associated Pneumonia (VAP) which is most common, deadly and costly HAI among ICU patients.
The estimated worldwide costs associated with treating VAP exceeds Ten Billion Dollars annually.
Device | Designation | Indication | Research | Pre-clinical | Clinical | Commercialization | Partnership |
Biofilm-preventing | Medical device, indwelling | Prevention of VAP / VARI |  |  |  |  |  |
Antimicrobial absorbable | Medical device, implant | Prevention of CIED infections |  |  |  | ||
Coated pedicle screw | Medical device, implant | Prevention of implant-associated orthopedic infections |  |
Leadership
Robert Mitchell
Carl Genberg, B.Sc. J.D.
Olga Yanvoskaya
Glenn Brunner
News
A recent published study by Professor Jordi Vila and his colleagues at the University of Barcelona, Spain has found that
Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the
A recent published study by Professor Robert Bucki and colleagues has shown that CSA-131 has broad spectrum antifungal activity and
Contact us
Lets Get in Touch!
- info@n8medical.com
- N8 Medical, LLC1090 Center DrivePark City, UT 84098
mynewform
Basic contact form
N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.
